Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 4B 3.68B 3.45B 6.46B 431B 6.57B 44.22B 17.12B 211B 17.08B 16.71B 735B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.13B 3.8B 3.56B 6.67B 445B 6.78B 45.67B 17.68B 218B 17.64B 17.26B 759B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
3 months+0.42%
6 months+1.97%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 5.51
Extreme 5.51
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap.
04-27Issuer sale

Director

395,940 0.1261%
04-27Issuer sale

Director

392,483 0.1250%
04-27Issuer sale

Director

310,136 0.0988%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+156.91%+14.64% 4.55B
+2.96%+4.21%-8.16%-2.76% 43.24B
+2.69%+8.79%+325.45%+567.52% 35.25B
+1.10%+4.14%+6.73%+53.31% 30.22B
+2.19%-4.37%+10.42%-19.96% 28.01B
-4.75%-8.29%+3.90%+13.88% 24.08B
+3.72%+2.47% - - 14.16B
+1.96%+0.23%+49.90%+107.11% 13.01B
+2.77%+4.02%+9.61%+15.31% 12.7B
+1.36%+5.02%+103.77%+93.64% 12.54B
Average +1.39%-0.68%+73.17%+93.63% 21.78B
Weighted average by Cap. +1.47%-0.70%+71.20%+118.38%

Financials

2024 2025
Net sales 528M 464M 428M 400M 750M 50.05B 763M 5.13B 1.99B 24.55B 1.98B 1.94B 85.34B 634M 557M 513M 481M 900M 60.08B 916M 6.16B 2.39B 29.48B 2.38B 2.33B 102B
Net income -56.11M -49.29M -45.42M -42.52M -79.66M -5.31B -81M -545M -211M -2.61B -211M -206M -9.06B -27.11M -23.82M -21.95M -20.54M -38.49M -2.57B -39.14M -264M -102M -1.26B -102M -99.58M -4.38B
Net Debt 194M 170M 157M 147M 275M 18.35B 280M 1.88B 729M 9B 727M 711M 31.29B 149M 131M 120M 113M 211M 14.1B 215M 1.45B 560M 6.92B 559M 547M 24.04B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!